Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | CETP | P11597 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515527 | 1.00 | MME (0.44) | MMELTA4HCETPSMN1; SMN2RAB9A | |
| SCHEMBL14742983 | 0.98 | MME (0.45) | MMELTA4HCETPSMN1; SMN2RAB9A | |
| SCHEMBL5857636 | 0.84 | MME (0.42) | MMELTA4HSMN1; SMN2RAB9A | |
| SCHEMBL25901525 | 0.78 | MME (0.33) | MMESMN1; SMN2RAB9AACECPA1 | |
| SCHEMBL17181685 | 0.77 | MME (0.42) | MMELTA4HSMN1; SMN2RAB9A | |
| SCHEMBL997755 | 0.77 | MME (0.42) | MMELTA4HSMN1; SMN2RAB9A | |
| SCHEMBL19347273 | 0.76 | CETP (0.32) | CETP | |
| SCHEMBL13070545 | 0.75 | — | — | |
| SCHEMBL158231 | 0.75 | MME (0.43) | MMELTA4HCETPSMN1; SMN2RAB9A | |
| SCHEMBL6037209 | 0.75 | MME (0.43) | MMELTA4HCETPSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426821-B2 | Variants of TACE pro-domain as TNF-A inhibitor and their medical use | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-10-01 | — | — | US | disclosed |
| EP-2839839-B1 | Nuclear targeting sequences | YEDA RES AND DEVELOPMENT COMPANY LIMITED (IL) | 2018-01-17 | — | — | EP | disclosed |
| US-20170304412-A1 | VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-10-26 | — | — | US | disclosed |
| US-9687583-B2 | Adhesive biopolymers and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-06-27 | — | — | US | disclosed |
| US-9493557-B2 | Chemokine binding polypeptides for treating autoimmunity and inflammation | BIOKINE THERAPEUTICS LTD. (IL) | 2016-11-15 | — | — | US | disclosed |
| US-9403887-B2 | Endothelial cell-specific polynucleotides and use thereof | VASCULAR BIOGENICS LTD. (IL) | 2016-08-02 | — | — | US | disclosed |
| EP-2751132-A2 | ADHESIVE BIOPOLYMERS AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2014-07-09 | — | — | EP | disclosed |
| US-8748371-B2 | Nuclear targeting sequences | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-06-10 | — | — | US | disclosed |
| US-20140154249-A1 | NOVEL CHEMOKINE BINDING POLYPEPTIDES CAPABLE OF INHIBITING THE COURSE OF AUTOIMMUNITY, INFLAMMATION AND CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2014-06-05 | — | — | US | disclosed |
| WO-2013030840-A2 | ADHESIVE BIOPOLYMERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-03-07 | — | — | WO | disclosed |
| US-20100099627-A1 | NUCLEAR TARGETING SEQUENCES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-04-22 | — | — | US | disclosed |
| CN-101163793-A | Molecular optoelectronic device and method of fabricating the same | UNIV RAMOT (IL) | 2008-04-16 | — | — | CN | disclosed |